Welcome to the second phase of the REUMAVID survey which aims to understand the effects of the current pandemic on the evolution of each rheumatic disease, support services, healthcare, the quality of life and the well-being of people living with rheumatic diseases.
This study is promoted by the National Axial Spondyloarthritis Society (NASS), the National Rheumatoid Arthritis Society (NRAS), and Arthritis Action, and conducted by the Health & Territory Research (HTR) of the University of Seville, Spain with the support of Novartis Pharma AG. The REUMAVID study is being conducted simultaneously in seven European countries (Cyprus, France, Greece, Italy, Portugal, Spain and the United Kingdom) in order to better understand the effects of COVID-19 on people living with rheumatic diseases by providing an international perspective. The first phase of the REUMAVID study took place between April-July 2020 and we would like to thank the 1,800 patients who participated as the results are being widely disseminated to advocate for the needs of patients with rheumatic diseases during this time.
Your contribution to this second survey will help to design solutions that will help improve the well-being and quality of life of people living with rheumatic diseases once this current pandemic is over or in the event it extends for a longer period of time. The current survey is a comprehensive questionnaire, which requests information on personal, family, social, health and clinical habits and will take you between 15 and 20 minutes to complete. Your effort in completing the survey will not directly affect your care, as your answers will not reach your responsible physician. Your participation is voluntary and will not involve any additional costs or financial compensation.
Before starting, we would like to confirm that the data collected will be treated confidentially, stored anonymously and will only be used for research purposes on an aggregate level. The personal data you provide will not be transferred to third parties as stipulated by the Data Protection Act 2018. We have adopted the security levels appropriate to the data you provide to prevent the loss, misuse, alteration, unauthorized access and theft. Only in the case of any adverse event (side effects) from medication reporting may the anonymous data be transferred to regulatory authorities, partners or relevant pharmaceutical companies within or outside EU and EEC ensuring that confidentiality of the data and applicable data privacy requirements will be complied with.
You may withdraw from the online survey at any time and withhold information as you see fit. However, once you have completed the survey and submitted your answers, you will be unable to access, change or remove your information, since it will not be possible to identify your answers.